A randomized, double-blind, placebo controlled and active comparator study phase III trial of Deflazacort in Duchenne Muscular Dystrophy

Trial Profile

A randomized, double-blind, placebo controlled and active comparator study phase III trial of Deflazacort in Duchenne Muscular Dystrophy

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Deflazacort (Primary) ; Prednisone
  • Indications Duchenne muscular dystrophy
  • Focus Registrational; Therapeutic Use
  • Sponsors Marathon Pharmaceuticals
  • Most Recent Events

    • 09 Feb 2017 According to a CureDuchenne Ventures media release, Marathon Pharmaceuticals company got the U.S. Food and Drug Administration approval for EMFLAZA™ (deflazacort) use in patients who are five years and older with Duchenne muscular dystrophy regardless of genetic mutation.
    • 26 Aug 2016 Results assessing effects of Deflazacort and Prednisone on muscle strength and motor function published in the Neurology (2016).
    • 21 Apr 2016 Results (post hoc subgroup analysis) assessing the effects of deflazacort and prednisone on pulmonary function presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top